Compugen (CGEN) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Compugen (CGEN) has outperformed Protalix BioTherapeutics (DE) (PLX) over the past year, gaining 22.2% versus a gain of 8.4%. Over five years, PLX leads with a +120.3% price change compared with -66.2% for CGEN. Protalix BioTherapeutics (DE) is the larger company by market cap ($218.3 million vs $203.7 million), about 1.1 times the size.
On valuation, Compugen trades at a lower trailing P/E (5.7x vs 11.8x for Protalix BioTherapeutics (DE)).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEN | PLX |
|---|---|---|
| Share price | $2.15 | $2.71 |
| Market cap | $203.66M | $218.35M |
| 1-day change | -3.15% | -0.73% |
| YTD return | +40.52% | +50.56% |
| 1-year return | +22.16% | +8.40% |
| 5-year return | -66.19% | +120.33% |
| P/E ratio (TTM) | 5.66 | 11.78 |
| Forward P/E | — | 4.37 |
| EPS (TTM) | $0.38 | $0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.24 | $3.19 |
| 52-week low | $1.43 | $1.60 |
| Distance from 52-week high | -33.64% | -15.05% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +113.95% | +305.90% |
| Average volume | 247.77K | 731.66K |
| Shares outstanding | 94.72M | 80.57M |
| Employees | 75 | 226 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEN has outperformed PLX by 13.8 percentage points over the past year.
- Protalix BioTherapeutics (DE) trades at a higher earnings multiple (11.8x vs 5.7x trailing P/E).
About Compugen
CGEN stock →Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Healthcare · Biotechnology · 75 employees
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Healthcare · Biotechnology · 226 employees
CGEN vs PLX FAQ
Which is bigger, Compugen or Protalix BioTherapeutics (DE)?
Protalix BioTherapeutics (DE) (PLX) is larger, with a market capitalization of $218.35M compared with $203.66M for Compugen (CGEN).
Which stock has performed better over the past year, CGEN or PLX?
CGEN returned +22.16% over the past 12 months, compared with +8.40% for PLX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CGEN or PLX?
CGEN has the lower trailing P/E at 5.7, versus 11.8 for PLX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Compugen and Protalix BioTherapeutics (DE) in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.